Peginterferon gamma - Bolder BioTechnology
Alternative Names: BBT-046; Gamma Interferon Long Acting; TNF-γ long actingLatest Information Update: 19 Jun 2023
Price :
$50 *
At a glance
- Originator Bolder BioTechnology
- Class Antifungals; Interferons; Polyethylene glycols
- Mechanism of Action Interferon gamma replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Mycoses
Most Recent Events
- 19 Jun 2023 Peginterferon gamma is still in preclinical development for Mycoses in USA (Parenteral) (Bolder Biotechnology pipeline, June 2023)
- 28 May 2022 No recent reports of development identified for preclinical development in Mycoses in USA (Parenteral, Injection)
- 20 May 2020 Peginterferon gamma - Bolder BioTechnology is available for licensing as of 20 May 2020. http://www.bolderbio.com/